Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Claytons research contributions to PT-141 development include: Principal investigator for pivotal Phase 2 dose-finding trial establishing optimal 1.75 mg dose Lead investigator for RECONNECT Phase 3 trials supporting FDA approval Development of responder analysis methodology for patient-reported outcomes in sexual dysfunction Neurobehavioral research elucidating central mechanisms of sexual desire Extensive publication record on bremelanotide efficacy, safety, and clinical applications Her work has established PT-141 as the second FDA-approved pharmacological treatment for HSDD and the first melanocortin-based therapy for sexual dysfunction, representing a significant advance in womens sexual health treatment options
IMPORTANT NOTE: This situation is quickly and constantly changing and will likely continue to do so
A personalised treatment plan will be discussed at your initial consultation
Vitamin B12 injections: Are you feeling tired every day even after those energy drinks and several cups of coffee
Medication eligibility, risks, and results vary by patient
US$ 29.64
US$ 23.93
US$ 28.82
US$ 21.11
US$ 26.57
US$ 20.29
